Skip to main content
NCBI home page
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 1991 May;67(787):466–468. doi: 10.1136/pgmj.67.787.466

Shrinkage of thyrotrophin secreting pituitary adenoma treated with octreotide.

S M Orme 1, J T Lamb 1, M Nelson 1, P E Belchetz 1
PMCID: PMC2398861  PMID: 1852668

Abstract

Thyrotrophin secreting pituitary adenomas are a rare cause of recurrent thyrotoxicosis. We report on a 47 year old woman with an 8-year history of this condition. In this case the somatostatin analogue, octreotide, normalized thyroid hormone levels. It was associated with marked tumour shrinkage, with striking reduction of the suprasellar extension and improved appearances in the region of the left cavernous sinus shown by high resolution computerized tomography. Following surgery she developed a biochemical relapse which responded to the reinstitution of octreotide. On long term treatment she developed stomach cramps and gallstones. Octreotide was discontinued. We review previous reports of this condition and discuss the role of octreotide in its management.

Full text

PDF
466

Images in this article

467Figure 2
on p.467
467Figure 3
on p.467

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barkan A. L., Lloyd R. V., Chandler W. F., Hatfield M. K., Gebarski S. S., Kelch R. P., Beitins I. Z. Preoperative treatment of acromegaly with long-acting somatostatin analog SMS 201-995: shrinkage of invasive pituitary macroadenomas and improved surgical remission rate. J Clin Endocrinol Metab. 1988 Nov;67(5):1040–1048. doi: 10.1210/jcem-67-5-1040. [DOI] [PubMed] [Google Scholar]
  2. Beck-Peccoz P., Mariotti S., Guillausseau P. J., Medri G., Piscitelli G., Bertoli A., Barbarino A., Rondena M., Chanson P., Pinchera A. Treatment of hyperthyroidism due to inappropriate secretion of thyrotropin with the somatostatin analog SMS 201-995. J Clin Endocrinol Metab. 1989 Jan;68(1):208–214. doi: 10.1210/jcem-68-1-208. [DOI] [PubMed] [Google Scholar]
  3. Bevan J. S., Burke C. W., Esiri M. M., Adams C. B., Ballabio M., Nissim M., Faglia G. Studies of two thyrotrophin-secreting pituitary adenomas: evidence for dopamine receptor deficiency. Clin Endocrinol (Oxf) 1989 Jul;31(1):59–70. doi: 10.1111/j.1365-2265.1989.tb00454.x. [DOI] [PubMed] [Google Scholar]
  4. Comi R. J., Gesundheit N., Murray L., Gorden P., Weintraub B. D. Response of thyrotropin-secreting pituitary adenomas to a long-acting somatostatin analogue. N Engl J Med. 1987 Jul 2;317(1):12–17. doi: 10.1056/NEJM198707023170103. [DOI] [PubMed] [Google Scholar]
  5. Elewaut A., Mussche M., Vermeulen A. Familial partial target organ resistance to thyroid hormones. J Clin Endocrinol Metab. 1976 Sep;43(3):575–581. doi: 10.1210/jcem-43-3-575. [DOI] [PubMed] [Google Scholar]
  6. Emerson C. H., Utiger R. D. Hyperthyroidism and excessive thyrotropin secretion. N Engl J Med. 1972 Aug 17;287(7):328–333. doi: 10.1056/NEJM197208172870704. [DOI] [PubMed] [Google Scholar]
  7. Gershengorn M. C., Weintraub B. D. Thyrotropin-induced hyperthyroidism caused by selective pituitary resistance to thyroid hormone. A new syndrome of "inappropriate secretion of TSH". J Clin Invest. 1975 Sep;56(3):633–642. doi: 10.1172/JCI108133. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Gorden P., Comi R. J., Maton P. N., Go V. L. NIH conference. Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut. Ann Intern Med. 1989 Jan 1;110(1):35–50. doi: 10.7326/0003-4819-110-1-35. [DOI] [PubMed] [Google Scholar]
  9. Guillausseau P. J., Chanson P., Timsit J., Warnet A., Lajeunie E., Duet M., Lubetski J. Visual improvement with SMS 201-995 in a patient with a thyrotropin-secreting pituitary adenoma. N Engl J Med. 1987 Jul 2;317(1):53–54. doi: 10.1056/NEJM198707023170113. [DOI] [PubMed] [Google Scholar]
  10. Inappropriate secretion of thyroid-stimulating hormone. Ann Intern Med. 1981 Sep;95(3):339–351. doi: 10.7326/0003-4819-95-3-339. [DOI] [PubMed] [Google Scholar]
  11. Kourides I. A., Ridgway E. C., Weintraub B. D., Bigos S. T., Gershengorn M. C., Maloof F. Thyrotropin-induced hyperthyroidism: use of alpha and beta subunit levels to identify patients with pituitary tumors. J Clin Endocrinol Metab. 1977 Sep;45(3):534–543. doi: 10.1210/jcem-45-3-534. [DOI] [PubMed] [Google Scholar]
  12. Krejs G. J., Orci L., Conlon J. M., Ravazzola M., Davis G. R., Raskin P., Collins S. M., McCarthy D. M., Baetens D., Rubenstein A. Somatostatinoma syndrome. Biochemical, morphologic and clinical features. N Engl J Med. 1979 Aug 9;301(6):285–292. doi: 10.1056/NEJM197908093010601. [DOI] [PubMed] [Google Scholar]
  13. Morley J. E. Neuroendocrine control of thyrotropin secretion. Endocr Rev. 1981 Fall;2(4):396–436. doi: 10.1210/edrv-2-4-396. [DOI] [PubMed] [Google Scholar]
  14. Samaan N. A., Osborne B. M., Mackay B., Leavens M. E., Duello T. M., Halmi N. S. Endocrine and morphologic studies of pituitary adenomas secondary to primary hypothyroidism. J Clin Endocrinol Metab. 1977 Nov;45(5):903–911. doi: 10.1210/jcem-45-5-903. [DOI] [PubMed] [Google Scholar]
  15. Smallridge R. C., Smith C. E. Hyperthyroidism due to thyrotropin-secreting pituitary tumors. Diagnostic and therapeutic considerations. Arch Intern Med. 1983 Mar;143(3):503–507. [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES